{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/prescribing-information/clopidogrel/","result":{"pageContext":{"chapter":{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel","depth":2,"htmlHeader":"<!-- begin field 69910f34-727a-4d45-99af-a781008e52d0 --><h2>Clopidogrel</h2><!-- end field 69910f34-727a-4d45-99af-a781008e52d0 -->","summary":"","htmlStringContent":"<!-- begin item 76fa206d-8f6d-44d8-af17-a781008e3900 --><!-- end item 76fa206d-8f6d-44d8-af17-a781008e3900 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"464cccb4-5bbe-5f16-8116-cb190d73e347","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 2881f789-2ae6-4de1-8c04-a781008f74a2 --><h3>Contraindications and cautions </h3><!-- end field 2881f789-2ae6-4de1-8c04-a781008f74a2 -->","summary":"","htmlStringContent":"<!-- begin item 432c3b7b-5d73-47ec-986a-a781008f7255 --><!-- begin field 34666843-ac2f-42e9-a159-a781008f74a2 --><ul><li><strong>Do not prescribe clopidogrel to people with:</strong><ul><li>Active pathological bleeding, such as peptic ulcer or intracranial haemorrhage.</li><li>Severe hepatic impairment.</li></ul></li><li><strong>Prescribe clopidogrel with caution </strong><strong>to people:</strong><ul><li>At risk of increased bleeding from trauma, surgery, or other pathological conditions.</li><li>Taking other drugs known to increase bleeding risk (for example, nonsteroidal anti-inflammatory drugs, corticosteroids, or selective serotonin reuptake inhibitors).</li><li>With renal impairment.</li><li>With hepatic impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>] </p><!-- end field 34666843-ac2f-42e9-a159-a781008f74a2 --><!-- end item 432c3b7b-5d73-47ec-986a-a781008f7255 -->","subChapters":[]},{"id":"46e62205-81bb-59dc-b026-f76eb367cd25","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2f5ef6d4-c8da-4c48-a164-a781008f9611 --><h3>Adverse effects </h3><!-- end field 2f5ef6d4-c8da-4c48-a164-a781008f9611 -->","summary":"","htmlStringContent":"<!-- begin item ccb42f59-2bcc-456a-be71-a781008f953d --><!-- begin field 3065fd4a-3826-4e39-8cb1-a781008f9611 --><ul><li><strong>Blood and lymphatic system</strong> — thrombocytopenia, leucopenia, eosinophilia (uncommon).<ul><li><strong>Rarely or very rarely:</strong> neutropenia, thrombotic thrombocytopenia purpura (TTP), aplastic anaemia, acquired haemophilia A, granulocytopenia.</li></ul></li><li><strong>Eye</strong> — conjunctival, ocular, or retinal bleeding (uncommon). </li><li><strong>Gastrointestinal (GI)</strong>— GI haemorrhage, abdominal pain, diarrhoea, dyspepsia (common); gastric ulcer, duodenal ulcer, gastritis, vomiting, nausea, flatulence (uncommon).<ul><li><strong>Very rarely</strong>: GI and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis.</li></ul></li><li><strong>Respiratory </strong>— epistaxis (common).<ul><li><strong>Rarely:</strong> haemoptysis, pulmonary haemorrhage, bronchospasm, interstitial pneumonitis, eosinophilic pneumonia.</li></ul></li><li><strong>Skin and subcutaneous tissue</strong> — bruising (common); rash, pruritus, skin bleeding (uncommon).<ul><li><strong>Very rarely:</strong> toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalized exanthematous pustulosis (AGEP), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS).</li></ul></li><li><strong>Vascular</strong> — haematoma (common).<ul><li><strong>Very rarely</strong>: serious haemorrhage, vasculitis, hypotension.</li></ul></li><li>Insulin autoimmune syndrome which can lead to severe hypoglycaemia, particularly in patients with HLA DRA4 subtype (This is more frequent in the Japanese population).</li><li><strong>Other rare or very rare adverse effects include:</strong><ul><li>Acute liver failure, hepatitis.</li><li>Fever.</li><li>Gynaecomastia.</li><li>Hallucinations, confusion.</li><li>Kounis syndrome.</li><li>Serum sickness, anaphylactoid reactions.</li><li>Vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 3065fd4a-3826-4e39-8cb1-a781008f9611 --><!-- end item ccb42f59-2bcc-456a-be71-a781008f953d -->","subChapters":[]},{"id":"4a0dbf14-1e6b-5921-bbb0-a7b500227368","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 131f93d4-c055-453e-a854-a781008fcee7 --><h3>Drug interactions</h3><!-- end field 131f93d4-c055-453e-a854-a781008fcee7 -->","summary":"","htmlStringContent":"<!-- begin item 7aef28da-69f6-4fec-828c-a781008fcdc2 --><!-- begin field 2ae12a96-55fe-4856-8180-a781008fcee7 --><ul><li><strong>Loperamide</strong> — levels may be increased if taken concurrently with clopidogrel. Monitor for loperamide adverse effects and reduce the dose if required.</li><li><strong>Montelukast</strong> — levels may be increased by clopidogrel. Monitor for adverse effects and reduce the montelukast dose if required.</li><li><strong>Pioglitazone, rosiglitazone</strong> — levels of pioglitazone are increased. Monitor for adverse effects and reduce the dose if required.</li><li><strong>Repaglinide </strong>— levels may be increased by clopidogrel. Monitor blood glucose concentrations closely and adjust repaglinide dose if required.</li><li><strong>Rifampicin</strong> — metabolism of clopidogrel to its active metabolite is induced slightly increasing antiplatelet effect. Bear this in mind if unexplained bleeding occurs. The manufacturer discourages concurrent use.</li><li><strong>Increased risk of bleeding if clopidogrel is combined with other drugs that also increase the risk of bleeding.</strong> Examples include: <ul><li>Antiplatelets — aspirin, prasugrel, ticagrelor.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — ibuprofen, diclofenac.</li><li>Oral and parenteral anticoagulants— warfarin, or heparin.</li><li>Selective serotonin reuptake inhibitors (SSRIs) — citalopram, sertraline.</li><li>Serotonin and noradrenaline reuptake inhibitors (SNRIs) —  venlafaxine, duloxetine.</li></ul></li><li><strong>Drugs which when taken concurrently with clopidogrel may reduce the antiplatelet effect include:</strong><ul><li>Antifungals (voriconazole, fluconazole, ketoconazole) —avoid concurrent use.</li><li>Carbamazepine — avoid concurrent use.</li><li>Cimetidine — use an alternative H2 antagonist.</li><li>Efavirenz — avoid concurrent use.</li><li>Grapefruit juice — inhibition of platelet aggregation reduced. Grapefruit juice should be avoided when taking clopidogrel.</li><li>Moclobemide — avoid concurrent use.</li><li>Omeprazole and esomeprazole — use only when the risk of gastrointestinal bleeding outweighs the risk of clopidogrel treatment failure.</li><li>Opioids have the potential to delay gastric emptying which may reduce the absorption of clopidogrel. </li><li>Ticlopidine — avoid concurrent use.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2020</a>]</p><!-- end field 2ae12a96-55fe-4856-8180-a781008fcee7 --><!-- end item 7aef28da-69f6-4fec-828c-a781008fcdc2 -->","subChapters":[]},{"id":"2c8c86f2-986b-502c-9a2c-dd8a0a6bba7e","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field acbdf622-84ca-4767-a0df-a8e800ff3aa4 --><h3>Pregnancy and breastfeeding</h3><!-- end field acbdf622-84ca-4767-a0df-a8e800ff3aa4 -->","summary":"","htmlStringContent":"<!-- begin item bced1000-2b2e-4965-b41f-a8e800ff399d --><!-- begin field e2f37283-1840-4dac-9153-a8e800ff3aa4 --><h4>Pregnancy</h4><ul><li>Clopidogrel should be avoided in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>It is unknown whether clopidogrel is excreted in breastmilk. The manufacturer advises that breastfeeding should be discontinued during treatment with clopidogrel.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field e2f37283-1840-4dac-9153-a8e800ff3aa4 --><!-- end item bced1000-2b2e-4965-b41f-a8e800ff399d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}